RxActuator Acquisition Disrupts Veterinary Care with Multispecies 'Hospital-at-Home' Infusion Platform

Journey Legacy Partners acquires RxActuator to scale first non-powered, 48-hour wearable infusion system for multispecies home recovery

Mar. 19, 2026 at 3:03pm

Got story updates? Submit your updates here. ›

Journey Legacy Partners, LLC (JLP), a private investment and operating firm, has announced the formation of Journey Actuating Technologies, Inc. (dba RxActuator) and the acquisition of 100% of the assets and intellectual property of RxActuator, Inc. and Medipacs. The acquisition marks the commercial relaunch of the RxActuator Mini-Infuser®, a validated, commercial-stage platform positioned at the forefront of the rapidly expanding 'hospital-at-home' movement in veterinary medicine.

Why it matters

The RxActuator Mini-Infuser is the industry's first wearable, disposable, non-powered continuous-rate infusion (CRI) system designed to bridge the gap between ICU-level care and the limitations of at-home oral dosing. The system enables reliable 48-hour continuous drug delivery for analgesics, antibiotics, and other critical therapies, allowing veterinarians to safely transition patients out of the clinic while improving patient comfort and outcomes.

The details

The device is powered by a patented, water-activated polymer actuator that delivers precise, constant-rate infusion without electronics, batteries, software, or programming—reducing complexity, cost, and failure risk. A secure mechanical locking mechanism further mitigates risks associated with controlled substances, supporting safe outpatient protocols. The platform has demonstrated real-world adoption, with approximately 500 units previously deployed across ~90 clinics in 26 U.S. states, as well as Canada and Australia.

  • The acquisition was announced on March 19, 2026.

The players

Journey Legacy Partners, LLC (JLP)

A private investment and operating firm led by medical device and life sciences executive Jeff Journey.

Journey Actuating Technologies, Inc. (dba RxActuator)

The company formed by JLP to acquire the assets and intellectual property of RxActuator, Inc. and Medipacs.

Jeff Journey

The CEO of RxActuator and a veteran of Thermo Fisher Scientific, Johnson & Johnson MedTech, GE Aerospace, and the U.S. Air Force.

Joshua Alcorn

The Chief Commercial Officer of RxActuator, with over 15 years of strategic healthcare, commercial, and operational leadership experience.

Mark Banister

The original inventor of the core actuator technology and founder of RxActuator.

Got photos? Submit your photos here. ›

What they’re saying

“We're at a tipping point where staffing shortages, rising costs, and capacity limits are accelerating outpatient care—bringing hospital-grade infusion into the home with better outcomes and confidence”

— Jeff Journey, CEO, RxActuator

What’s next

The company is executing a disciplined relaunch focused on scaling manufacturing, optimizing the supply chain, and reactivating commercial channels to meet demonstrated market demand.

The takeaway

The acquisition of RxActuator by Journey Legacy Partners marks a significant development in the veterinary care industry, as the RxActuator Mini-Infuser platform enables the delivery of hospital-grade infusion therapy in the comfort of a pet's home, addressing the challenges of staffing shortages, rising costs, and capacity constraints in the veterinary care system.